PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Datopotamab Deruxtecan→

Datopotamab Deruxtecan PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2238831-60-0
Molecular formula
Not available
Molecular weight
Not available
Drug class
TROP2-directed antibody–drug conjugate (ADC)topoisomerase I inhibitor payload
Mechanism of action
The antibody binds TROP2 on tumour cells and is internalised. Intracellular cleavage releases a deruxtecan-derived topoisomerase I inhibitor payload, causing DNA damage and tumour-cell death; a membrane-permeable payload can also produce bystander cytotoxicity.
Indications / reported uses
  • Treatment of adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy under the US FDA Datroway indication approved 22 May 2026
  • Treatment of adults with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer after prior EGFR-directed therapy and platinum-based chemotherapy under the earlier US indication; confirm current product label for biomarker and prior-treatment criteria

Sources: US FDA — Datopotamab deruxtecan approval for TNBC, 22 May 2026 · US DailyMed — DATROWAY (datopotamab deruxtecan-dlnk) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Datopotamab Deruxtecan PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Datopotamab Deruxtecan Permitted Daily Exposure (PDE) report (the Datopotamab Deruxtecan PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Datopotamab Deruxtecan Occupational Exposure Limit (OEL) report (the Datopotamab Deruxtecan OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.